Familial hemophagocytic lymphohistiocytosis (FHL) is a heterogeneous autosomal recessive disorder caused by mutations in PRF1 (FHL2), UNC13D (FHL3), STX11 (FHL4), and STXBP2 (FHL5). All of these genes are related to formation and function of secretory lysosomes within cytotoxic T lymphocytes and NK cells [1] . Here, we describe the first UNC13D-deficient case of FHL from the Iranian national registry of primary immunodeficiency disorders (PIDs) presenting with a unique phenotype of antibody deficiency and epileptic seizures.
A 1-month-old boy was admitted for 120 days with high fever and diarrhea associated with anemia and organomegaly. The patient was the first child of consanguineous parents, and analysis of the family history revealed that the paternal grandfather had had cancer and the grandmother had had chronic asthma. In addition, his maternal uncle had died of unknown causes several months after birth ( Figure S1 ). At the age of 6 months, the patient was admitted to the intensive care unit because of pneumonia and recurrent diarrhea. He was diagnosed with hypogammaglobulinemia (low Ig levels and B-cell count, Table) and referred to our center for further assessment and treatment. Given the low B-cell count, subset analysis and functional tests were not conducted. The patient received monthly intravenous immunoglobulin (IVIG) replacement therapy for hypogammaglobulinemia. A chest x-ray indicated a consolidation in the upper right lobe and confirmed pneumonia. A computed tomography (CT) scan revealed no significant manifestations in the brain.
At the age of 8 months and despite regular IVIG replacement therapy, the patient presented severe complications including high fever, epileptic seizures (involving the hands and head), respiratory distress, and fidgeting. Subsequently, he received oxygen (for respiratory distress) and phenytoin (for the epileptic seizures). In addition to IVIG replacement therapy, the patient received a broad range of antibiotics because of prolonged fever. To further evaluate the etiology of his lymphoproliferative and neurologic symptoms, additional laboratory tests were performed (Table) . Based on additional [2] . However, the molecular diagnosis of FHL3 due to a homozygous c.1208T>C missense mutation in the UNC13D gene in exon 14 was confirmed in this proband. This variant substituted leucine into a proline at amino acid 403 (p.Leu403Pro; combined annotation dependent depletion score, 17.440; mutation significance cut-off, 0.001). The patient was again hospitalized at 12 months of age owing to fever, cough, skin rash, and fatigue. Based on the confirmed diagnosis, the subject became a candidate for hematopoietic stem cell transplantation. After several days, his level of consciousness decreased, manifested epileptic gaze deviation, and he eventually died at the age of 13 months owing to a substantial reduction in oxygen, respiratory failure, and bradycardia.
We report the first case of FHL3 with an atypical presentation of humoral immunodeficiency from our national registry. FHL3 accounts for nearly 30%-40% of cases of FHL. Its underlying cause is a mutation in the UNC13D gene located on 17q25. The gene encodes the Munc13-4 protein [3] . Compound heterozygous mutations in FHL patients are prevalent, as such mutations have previously been reported in UNC13D [4] . Nevertheless, homozygous mutations are common in populations with a high prevalence of consanguineous marriage [5] . Zur Stadt et al [6] previously reported this mutation in a Turkish patient. Most mutations in previously reported cases were located in deep intronic regions within intron 1 and with inversion in intron 30, suggesting that not only should the coding sequences of UNC13D be evaluated, but introns and noncoding regions should also be sequenced.
According to the HLH-2004 guideline, the presence of 5 out of 8 criteria is sufficient for diagnosis of the disease. However, our patient fulfilled 6 of these criteria. The least common symptoms of the disease are neurological symptoms, skin rash, and jaundice [7] . Although clinical manifestations of FHL3 are indistinguishable from other types of FHL, central nervous system involvement seems to be more common in FHL3 (10%-30%) [8] and includes seizures, decreased consciousness, facial palsy, dysphagia, and dysarthria. Neurological damage was not observed in our patient, although he did experience epileptic seizures. In addition, his vision was impaired and he died of bradycardia. These observations have not been reported to date in FHL.
We also observed a substantial reduction in CD19 + and CD20 + counts; no B-cell disorders have previously been reported in FLH3. However, immune dysregulation and antibody deficiency have been reported in patients with defects in regulatory T cells (eg, LRBA and CTLA4 deficiencies, and STAT3 gain-of-function disease) and higher susceptibility to herpesvirus family infections (eg, X-linked lymphoproliferative disease, CD27 and CD70 deficiencies) [9] . In the only targeted study that evaluated B cells in HLH patients, B-cell abnormalities were not observed in a patient with UNC13D deficiency [10] . Furthermore, based on the International Union of Immunological Societies (IUIS) classification, B cells are normal in FHL3 disease. This immunological finding represents an unusual clinical symptom in our case; however, further studies are required to confirm the possibility of other genetic or environmental modifying factors for antibody deficiency in the context of FHL3.
We present the first report of UNC13D deficiency with unusual signs including epileptic seizures, visual impairment, cardiac disorders, and B-cells abnormalities. Therefore, unusual signs and B-cell abnormalities should be evaluated in cases of suspected FHL3 to ensure that this disease does not go undiagnosed and that patients receive appropriate treatment and management.
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Mast cells play a significant role in allergic diseases and, along with macrophages, are important in the inflammatory process. Upon activation, mast cells degranulate and release mediators via different mechanisms in response to various stimuli. Allergic reactions are induced mainly by preformed mast cell mediators including histamine, tryptase, and chymase. Spikes in tryptase titers can be considered a marker of anaphylaxis [1, 2] , whereas increments in basal serum tryptase (BST) levels can be considered a marker of increased mast cell burden, as in mastocytosis [3] , or of circumscribed inflammation, as in coronary atherosclerosis. In the follow-up of patients with previous acute coronary syndrome (ACS), we found that persisting elevated BST levels correlated with an increased risk of major adverse cardiovascular events (MACE) [4, 5] . In other cases, high BST levels were shown to be biomarkers for the risk of severe allergic reactions to hymenoptera venom [6] . Given the heterogeneity of situations characterized by high BST levels, we aimed to detect specific values to formulate the prognosis or diagnosis of various clinical conditions.
We compared BST ranges in 2 clinical disorders. One population comprised patients with hymenoptera venom allergy (HVA) and a history of Mueller grade III and IV anaphylactic reactions [7] . The second population comprised patients with a history of ACS that we had previously described in 2 studies and now includes 9 new patients [8, 5] . The statistical evaluation was based on a descriptive analysis, followed by inference using the Fisher exact test for categorical variables. We also performed the t test for continuous variables and logistic regression followed by ROC analysis to dichotomize continuous variables with the aim of determining possible cut-off values.
A total of 579 patients (400 males/173 females; median age, 55 years [range, 5-92]) were included in this retrospective
